1243456-02-1 Usage
Uses
Used in Pharmaceutical Industry:
3-Ethyl-2-fluorophenol is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds due to its unique chemical structure and properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Ethyl-2-fluorophenol serves as an intermediate, playing a crucial role in the production of pesticides and other agrochemicals that are essential for crop protection and enhancement of agricultural yields.
Used in Dye Industry:
3-Ethyl-2-fluorophenol is employed in the dye industry as an intermediate for the production of dyes, which are used in a wide range of applications including textiles, plastics, and printing inks.
Used in Fragrance Industry:
3-Ethyl-2-fluorophenol is also used as a building block in the synthesis of fragrance compounds, adding to the complexity and variety of scents used in perfumes, cosmetics, and other scented products.
Used in Biotechnology and Medicine:
3-Ethyl-2-fluorophenol has been studied for its potential antimicrobial properties, indicating its value in the fields of medicine and biotechnology, particularly for the development of new antimicrobial agents to combat resistant strains of bacteria.
Check Digit Verification of cas no
The CAS Registry Mumber 1243456-02-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,3,4,5 and 6 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1243456-02:
(9*1)+(8*2)+(7*4)+(6*3)+(5*4)+(4*5)+(3*6)+(2*0)+(1*2)=131
131 % 10 = 1
So 1243456-02-1 is a valid CAS Registry Number.
1243456-02-1Relevant articles and documents
Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism
Wellaway, Christopher R.,Baldwin, Ian R.,Bamborough, Paul,Barker, Daniel,Bartholomew, Michelle A.,Chung, Chun-Wa,Dümpelfeld, Birgit,Evans, John P.,Fazakerley, Neal J.,Homes, Paul,Keeling, Steven P.,Lewell, Xiao Q.,McNab, Finlay W.,Morley, Joanne,Needham, Deborah,Neu, Margarete,Van Oosterhout, Antoon J. M.,Pal, Anshu,Reinhard, Friedrich B. M.,Rianjongdee, Francesco,Robertson, Craig M.,Rowland, Paul,Shah, Rishi R.,Sherriff, Emma B.,Sloan, Lisa A.,Teague, Simon,Thomas, Daniel A.,Wellaway, Natalie,Wojno-Picon, Justyna,Woolven, James M.,Coe, Diane M.
, p. 633 - 664 (2022/01/03)
The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) play an essential role in the receptor signaling of cytokines that have been implicated in the pathogenesis of severe asthma, and there is emerging interest in the development of small-molecule-inhaled JAK inhibitors as treatments. Here, we describe the optimization of a quinazoline series of JAK inhibitors and the results of mouse lung pharmacokinetic (PK) studies where only low concentrations of parent compound were observed. Subsequent investigations revealed that the low exposure was due to metabolism by aldehyde oxidase (AO), so we sought to identify quinazolines that were not metabolized by AO. We found that specific substituents at the quinazoline 2-position prevented AO metabolism and this was rationalized through computational docking studies in the AO binding site, but they compromised kinome selectivity. Results presented here highlight that AO metabolism is a potential issue in the lung.
